Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
-
The Eos Energy complaint alleges that Eos Energy was unable to achieve the ramp in production and capacity utilization required to achieve guidance.
-
The case alleges Stellantis overstated its ability to capitalize on the electrification market.
-
The case alleges Medpace oversold its projected book-to-bill ratio for fourth quarter 2025.
-
The case alleges that NuScale failed to disclose that it entrusted its NPM commercialization to an entity that lacked significant prior experience.
-
The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
-
The case alleges Boston Scientific misled investors about its US EP segment's growth and competitive risks.
-
The monday.com complaint alleges that defendants misled investors by providing materially flawed statements of confidence and growth projections.
-
The case alleges Medpace oversold its projected book-to-bill ratio for fourth quarter 2025.
-
The case alleges Stellantis overstated its ability to capitalize on the electrification market.